Universal Access and Affordable Medicines
Our campaign promotes transparency, accountability and the public interest in the field of pharmaceuticals. Our evidence-based advocacy aims to guarantee better and affordable medicines for Europe by questioning and reforming the current pharmaceutical business model and calling for better access to medicines for all.
About our work on access to medicines
Publications
EPHA Position on Medicine Shortages
EPHA Response to public consultation on EMA Regulatory Science to 2025
BeNeLuxA et al.: the best is yet to come
Latest Developments
HERA should be independent and autonomous with a clear public health mission, EPHA says
HERA should be independent and autonomous with a clear public health mission, EPHA says in its response to the European Commission’s consultation
Increasing our options for cancer treatment in Europe
EPHA member, the Anticancer Fund calls for more research into repurposing of drugs to support cancer patients
Transparency is a fundamental pillar for the success of the EU Vaccines Strategy
39 health and consumer organisations call for the public and their elected representatives to be given more scrutiny of EU COVID19 vaccine contracts
Analysis & Opinion
Europe’s Beating Cancer Plan: Let’s focus on treatments that bring the most value to patients
Patients must be put at the heart of treatments developed as part of Europe’s Beating Cancer Plan
Best treatment for cancer patients in Europe?
If the EU wants to ensure “access to the best treatment for all” in its “Europe’s Beating Cancer plan” what changes need to be made to the assessment process for new cancer treatments?
The European Pharmaceutical Strategy: An inventory for action for Europe
What could we hope for from the upcoming EU Pharmaceutical Strategy, expected on 24 November
Events
EPHA #A2MDialogues
A new series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
Find out more and register for the latest discussion below
After COVID-19, what's next for EU medicines policies?
9 March 2021 | 16:00-17:00 CET
A one-on-one interview with Professor Guido Rasi, former Executive Director, European Medicines Agency (EMA)
Getting it right: Recommendations for a European BARDA
8 December 2020
The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines
25 November 2020
Pharma & COVID-19: Winners, losers, prospects
19 November 2020
The EU's IP strategy: Enabler or barrier?
27 October 2020
Unleashing meaningful innovation through regulatory reform
19 October 2020
Get monthly updates on key public health issues!
Past Events
Time for a new deal
14 November 2019
4th EPHA Universal Access and Affordable Medicines Forum. Challenging the status quo on medicines policy.
Putting health first
3 June 2019
Trailblazers, routes to better and affordable medicines by 2025
20 November 2018
How good are our medicines?
3 October 2018
Game changers for better and affordable medicines in Europe
21 November 2017
At the European Health Forum Gastein
How good are our medicines? An operational agenda for EU & national policy-makers
Medicines: new games, new rules - Pathways to better and affordable medicines.
“Healthy" innovation: putting patients before profits
Questions?
Meet our Universal Access and Affordable Medicines Policy Lead.
Yannis Natsis
Policy Manager
yannis@epha.org
+32 2 233 3886